DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company based in Minneapolis that is developing treatments for severe ischemic and vascular diseases. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of the human KLK1 protein being studied for acute ischemic stroke and preeclampsia. With shares recently trading near $9.70, the question for investors is whether the stock can climb toward the average analyst price target of $15.50.
Four credible, individually attributable analyst targets were reviewed to establish the central target. Cantor Fitzgerald analyst Josh Schimmer initiated coverage with an Overweight rating and a $25 target in November 2025, citing what he described as compelling preeclampsia data for DM199 and peak sales potential exceeding $1 billion by 2033. Lake Street's Thomas Flaten holds a $14 target, H.C. Wainwright's Matthew Caufield a $12 target, and Craig-Hallum's Chase Knickerbocker an $11 target, all with Buy ratings.
The arithmetic mean of these four targets is $15.50, with a low of $11 and a high of $25. That unusually wide range reflects genuine disagreement: the more conservative targets sit near the stock's recent 52-week high, while Cantor's $25 target prices in a far more bullish view of DM199's commercial potential. No independent consensus of $15.50 should be read as a guarantee; it is simply the average of published targets and is highly sensitive to which estimates are included.
With shares near $9.70 and a 52-week range of roughly $5.24 to $11.00, reaching $15.50 would require an advance of about 60% from current levels — a very large move. The path would most likely run through clinical milestones rather than financial results, because DiaMedica generates no meaningful revenue. The pivotal ReMEDy2 Phase 2/3 trial of DM199 in acute ischemic stroke is enrolling, with an interim analysis expected before the end of 2026, and positive data could materially re-rate the stock. In preeclampsia, Phase 2 data reported in 2026 showed statistically significant reductions in blood pressure and an improved uterine artery pulsatility index, supporting expansion toward a larger program.
Several factors could support a higher stock price. DM199 targets large, underserved indications — acute ischemic stroke and preeclampsia — where positive data could unlock substantial value. Management has indicated its cash, roughly $43 million to $51 million recently, should fund operations into 2027. Health Canada clearance in March 2026 to begin a Phase 2 preeclampsia study adds another catalyst. Analysts are unanimous in their bullish ratings, and short interest near 9.7% of shares outstanding could add fuel if positive news forces covering.
The principal obstacle is clinical risk. If the ReMEDy2 interim analysis or subsequent data disappoint, the stock could fall sharply regardless of analyst targets. DiaMedica remains pre-revenue with an operating loss of roughly $39 million over the trailing twelve months, and its share count has risen more than 20% over the past year, indicating dilution risk. The wide analyst range itself signals uncertainty, and a stock trading on binary trial outcomes can be highly volatile in both directions.
The $11 level stands out as a major resistance zone, marking the stock's 52-week high and coinciding with the lowest analyst target. Above that, the $12 and $14 targets form a ladder of further resistance. On the downside, the stock has recently traded above its 50-day and 200-day moving averages near $7.60 and $7.10, respectively, which now act as potential support. A sustained break above $11 would be the first technical confirmation that the broader analyst target range is becoming reachable.
Analyst price targets generally reflect a roughly 12-month research horizon, though the specific horizon varies by firm. For DiaMedica, the calendar is dominated by data events rather than earnings. Investors should monitor the ReMEDy2 interim analysis expected before the end of 2026, additional preeclampsia readouts and trial-initiation updates, quarterly cash burn and any capital raises, and revisions to analyst targets following those milestones.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior and AI-driven analysis. For a volatile, event-driven name like DiaMedica, these tools can help traders discover opportunities, monitor positions and spot shifting trends more efficiently than manual review. Explore the AI Daily Buy/Sell Signals to see how the platform is reading DMAC and the broader market.
The $15.50 target is the average of four published analyst targets ranging from $11 to $25, implying a roughly 60% advance from recent levels. It is supported by the potential of DM199 in stroke and preeclampsia, a cash runway into 2027 and unanimous bullish ratings, but it is challenged by clinical-execution risk, persistent losses and a wide spread of analyst opinions. Whether DMAC reaches $15.50 will depend chiefly on trial data rather than near-term financials, making the ReMEDy2 interim analysis the single most important item to watch.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with ANNX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then ANNX could also see price increases.
| Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
|---|---|---|---|---|
| DMAC | 100% | +0.21% | ||
| ANNX - DMAC | 47% Loosely correlated | -0.47% | ||
| EDIT - DMAC | 47% Loosely correlated | -8.91% | ||
| TSHA - DMAC | 45% Loosely correlated | -2.17% | ||
| VIR - DMAC | 44% Loosely correlated | -3.63% | ||
| SLDB - DMAC | 44% Loosely correlated | +2.14% | ||
More | ||||